Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRAGE phase III trial of marizomib added to standard chemoradiotherapy for newly diagnosed glioblastoma
NL-OMON52595Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of marizomib in glioblastoma (GBM) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Aug 2018; status: active, not recruiting.
02
Drugs
marizomib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON52595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52595.